268 related articles for article (PubMed ID: 25720792)
1. Organization and quality of HPV vaccination programs in Europe.
Elfström KM; Dillner J; Arnheim-Dahlström L
Vaccine; 2015 Mar; 33(14):1673-81. PubMed ID: 25720792
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide.
Owsianka B; Gańczak M
Przegl Epidemiol; 2015; 69(1):53-8, 151-5. PubMed ID: 25862448
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus vaccine introduction--the first five years.
Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.
Isidean SD; Tota JE; Gagnon JA; Franco EL
Expert Rev Vaccines; 2015 Jan; 14(1):119-33. PubMed ID: 25266065
[TBL] [Abstract][Full Text] [Related]
7. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.
Koulova A; Tsui J; Irwin K; Van Damme P; Biellik R; Aguado MT
Vaccine; 2008 Dec; 26(51):6529-41. PubMed ID: 18805453
[TBL] [Abstract][Full Text] [Related]
8. HPV vaccination in France: uptake, costs and issues for the National Health Insurance.
Fagot JP; Boutrelle A; Ricordeau P; Weill A; Allemand H
Vaccine; 2011 Apr; 29(19):3610-6. PubMed ID: 21382486
[TBL] [Abstract][Full Text] [Related]
9. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey.
Dorleans F; Giambi C; Dematte L; Cotter S; Stefanoff P; Mereckiene J; O'Flanagan D; Lopalco PL; D'Ancona F; Levy-Bruhl D;
Euro Surveill; 2010 Nov; 15(47):. PubMed ID: 21144444
[TBL] [Abstract][Full Text] [Related]
10. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
11. Implementation of the Australian HPV vaccination program for adult women: qualitative key informant interviews.
Leask J; Jackson C; Trevena L; McCaffery K; Brotherton J
Vaccine; 2009 Sep; 27(40):5505-12. PubMed ID: 19619501
[TBL] [Abstract][Full Text] [Related]
12. A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.
Favato G; Baio G; Capone A; Marcellusi A; Saverio Mennini F
Clin Ther; 2013 Jul; 35(7):904-14. PubMed ID: 23806328
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for cervical cancer prevention in Asia Pacific.
Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
[TBL] [Abstract][Full Text] [Related]
14. Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States.
Castle PE; Solomon D; Saslow D; Schiffman M
Cancer; 2008 Nov; 113(10 Suppl):3031-5. PubMed ID: 18980285
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
16. Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings.
Biellik R; Levin C; Mugisha E; LaMontagne DS; Bingham A; Kaipilyawar S; Gandhi S
Vaccine; 2009 Oct; 27(44):6203-9. PubMed ID: 19698808
[TBL] [Abstract][Full Text] [Related]
17. Mind the gaps: what's missing from current economic evaluations of universal HPV vaccination?
Marsh K; Chapman R; Baggaley RF; Largeron N; Bresse X
Vaccine; 2014 Jun; 32(30):3732-9. PubMed ID: 24837538
[TBL] [Abstract][Full Text] [Related]
18. Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.
Vanagas G; Padaiga Z
Scand J Public Health; 2012 Jul; 40(5):406-11. PubMed ID: 22821227
[TBL] [Abstract][Full Text] [Related]
19. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
Goldie SJ; O'Shea M; Diaz M; Kim SY
Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
[TBL] [Abstract][Full Text] [Related]
20. Literature review of HPV vaccine delivery strategies: considerations for school- and non-school based immunization program.
Paul P; Fabio A
Vaccine; 2014 Jan; 32(3):320-6. PubMed ID: 24295804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
